CNTN

Canton Strategic Holdings Inc

2.11

Jul 21 • 12:03PM ET +0.06 (2.99%)

Healthcare Biotechnology USA Micro NASD

Peers: KPTI ADAG CAMP CNTX IFRX PLYX PRQR RNA TENX TLSA

| Held by: VTI IWM VXF IWN ARKF VTWO IWC NODE VTWV AVSC

Index	RUT
Market Cap	162.83M
Enterprise Value	121.30M
Income	-80.72M
Sales	0.00M
Book/sh	8.29
Cash/sh	0.54
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Jan 12, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.25
P/C	3.92
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	37.75
Current Ratio	37.75
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-2.00
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	84.14% 58.22%
Sales past 3/5Y	- -
EPS Y/Y TTM	74.31%
Sales Y/Y TTM	-
EPS Q/Q	76.93%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	12.47%
Insider Trans	-1.03%
Inst Own	16.38%
Inst Trans	4.88%
ROA	-27.53%
ROE	-34.42%
ROIC	-17.18%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-16.79%
SMA50	-26.62%
SMA200	-35.01%
Trades

Shs Outstand	77.12M
Shs Float	67.51M
Short Float	10.34%
Short Ratio	7.88
Short Interest	6.98M
52W High	9.08 -76.75%
52W Low	1.08 95.40%
Volatility	7.99% 9.40%
ATR (14)	0.23
RSI (14)	35.35
Beta	1.48
Rel Volume	0.65
Avg Volume	885.53K
Volume	246,048

Perf Week	-8.20%
Perf Month	-36.98%
Perf Quarter	-39.85%
Perf Half Y	-27.70%
Perf YTD	-30.32%
Perf Year	26.88%
Perf 3Y	-98.54%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	5.00
Prev Close	2.05
Price	2.11
Change	2.99%

Jul-17-26 08:15AM	Canton Strategic Holdings, Inc. Delivers Second Quarter Canton Network Ecosystem Update (PR Newswire)
Jun-23-26 08:15AM	Canton Strategic Holdings, Inc. Announces Launch of Locking Service to Support Network Infrastructure Providers (PR Newswire)
Jun-18-26 08:15AM	Canton Strategic Holdings, Inc. Expected to Be Included in Russell 3000 and Russell 2000 (PR Newswire) -5.37%
Jun-16-26 08:34AM	Canton Strategic Holdings, Inc. Announces Authorization of Share Repurchase Program (PR Newswire)
May-13-26 08:15AM	Canton Strategic Holdings Reports First Quarter 2026 Financial and Operational Results (PR Newswire) +7.34%
09:15AM	Loading…
Apr-20-26 09:15AM	Canton Strategic Holdings, Inc. Presents Quarterly Canton Network Ecosystem Update (PR Newswire)
Mar-31-26 08:10AM	Canton Strategic Holdings Reports Full Year 2025 Financial and Operational Results (PR Newswire) +6.17%
Mar-12-26 08:00AM	BitGo to Securely Store Digital Asset Treasury Holdings for Canton Strategic Holdings, Inc. (Business Wire) -9.78%
Mar-10-26 07:30AM	Cathie Wood Bets $19 Million on 5 Beaten-Down Stocks (Barchart)
Mar-03-26 08:15AM	Canton Strategic Holdings, Inc. Chairman and CEO Mark Wendland Elected to Canton Foundation Board (PR Newswire) -10.12%
Feb-17-26 07:10AM	Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy (PR Newswire) +5.80%
Feb-06-26 08:15AM	Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer (PR Newswire) +5.34%
Feb-02-26 08:15AM	Tharimmune Elects Jill Sommers and William Wiley to Board of Directors (PR Newswire) +12.07%
Jan-31-26 02:02AM	Tharimmune Shareholders Approve Directors, Warrant-Linked Share Issuances and 7M Share Plan Boost (MarketBeat)
Jan-26-26 08:15AM	Tharimmune Announces Expanded Role as Super Validator on Canton Network (PR Newswire) +9.12%
04:12PM	Loading…
Jan-22-26 04:12PM	Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering (PR Newswire) +7.89%
Jan-20-26 08:45AM	Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering (PR Newswire)
Dec-18-25 08:15AM	Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network (PR Newswire) -5.93%
Dec-12-25 08:15AM	Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy (Business Wire) -5.53%
Nov-14-25 01:17PM	New Crypto Deals Put Retail at Risk After $17 Billion Wipeout (Bloomberg)
Nov-13-25 08:05AM	Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids (PR Newswire) -6.52%
Nov-10-25 06:02AM	Crypto treasury companies pivot to fringe tokens, stoking volatility fears (Reuters) -12.41%
Nov-06-25 04:16PM	Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy (PR Newswire)
Nov-03-25 09:54AM	Tharimmune Stock Gains 30%, on $540M Capital Raise to Build Canton Coin Treasury Strategy (CoinDesk) +8.47%
09:04AM	Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy (PR Newswire)
Aug-27-25 12:02PM	Tharimmune (THUR) Tumbles 20.7% on $5-Million Share Sale (Insider Monkey) -18.82%
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +63.35%
Aug-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +38.44%
Aug-20-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +206.84%
08:00AM	Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments (ACCESSWIRE)
08:01AM	Loading…
Aug-13-25 08:01AM	Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl (ACCESSWIRE) -5.71%
Aug-05-25 08:00AM	Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors (ACCESSWIRE) -8.27%
Aug-04-25 08:00AM	Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery (ACCESSWIRE) +7.26%
Jul-23-25 10:15PM	Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants (ACCESSWIRE) -7.83%
Jun-17-25 08:01AM	Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors (ACCESSWIRE) +9.09%
May-19-25 08:01AM	Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback (ACCESSWIRE) +7.79%
May-06-25 08:01AM	Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback (ACCESSWIRE) +5.77%
May-01-25 08:01AM	Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences (ACCESSWIRE) -10.40%
Apr-30-25 08:01AM	Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors (ACCESSWIRE) +16.89%
Apr-28-25 08:01AM	Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback (ACCESSWIRE) +13.34%
Apr-15-25 09:00AM	Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors (ACCESSWIRE)
Apr-07-25 08:00AM	Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology (ACCESSWIRE)
Mar-31-25 08:00AM	Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure (ACCESSWIRE)
Mar-04-25 07:00AM	Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology (ACCESSWIRE)
Jan-27-25 08:30AM	Tharimmune to Present at the Microcap Conference 2025 (ACCESSWIRE)
Dec-16-24 08:00AM	Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update (ACCESSWIRE)
Dec-06-24 04:15PM	Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs (ACCESSWIRE) +10.84%
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire)
Nov-18-24 08:00AM	Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease (ACCESSWIRE) +9.22%
Nov-13-24 08:00AM	Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics (ACCESSWIRE)
Nov-04-24 09:00AM	Tharimmune Announces Upcoming Conference Presentations (ACCESSWIRE) +9.67%
Oct-30-24 08:00AM	Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis (ACCESSWIRE) +68.97%
Oct-28-24 09:00AM	Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting (ACCESSWIRE)
Oct-25-24 08:00AM	Tharimmune Announces Upcoming Conference Presentations (ACCESSWIRE)
Sep-30-24 07:00AM	Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company (ACCESSWIRE)
Sep-16-24 07:00AM	Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab (ACCESSWIRE)
Jul-22-24 08:30AM	Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board (ACCESSWIRE)
Jul-17-24 08:30AM	Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor (ACCESSWIRE) -15.40%
Jul-16-24 08:30AM	Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104 (ACCESSWIRE)
Jun-10-24 08:00AM	Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis (ACCESSWIRE) -33.27%
May-29-24 08:30AM	Tharimmune to Present at 2024 BIO International Convention (ACCESSWIRE) +5.91%
May-24-24 08:12AM	Why Is Tharimmune (THAR) Stock Moving Today? (InvestorPlace) -6.87%
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-22-24 07:00AM	Tharimmune Announces 1-for-15 Reverse Stock Split (ACCESSWIRE) -16.52%
May-09-24 01:55PM	THAR Stock Earnings: Tharimmune Reported Results for Q4 2023 (InvestorPlace)
May-02-24 02:33PM	Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management (Newsfile)
Apr-30-24 08:31AM	Tharimmune To Participate in Two Upcoming Investor Conferences in May (ACCESSWIRE)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-23-24 07:31AM	Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs) (ACCESSWIRE)
Apr-15-24 08:31AM	Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics (ACCESSWIRE) -6.11%
Mar-06-24 07:00AM	Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now (GlobeNewswire)
Mar-05-24 08:31AM	Tharimmune to Present at the Emerging Growth Conference on March 7, 2024 (ACCESSWIRE)
07:00AM	Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now (GlobeNewswire)
Feb-20-24 08:01AM	Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate (ACCESSWIRE)
Feb-05-24 08:30AM	Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis (ACCESSWIRE) -6.77%
Jan-29-24 08:00AM	Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update (ACCESSWIRE)
Dec-11-23 08:01AM	Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients (ACCESSWIRE) -7.11%
Nov-30-23 04:01PM	Tharimmune, Inc. Announces Closing of $11 Million Public Offering (ACCESSWIRE) -12.32% -11.25%
09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile)
Nov-28-23 08:43AM	Why Is Tharimmune (THAR) Stock Down 70% Today? (InvestorPlace) -72.36%
Nov-27-23 09:40PM	Tharimmune, Inc. Announces Pricing of $10 Million Public Offering (ACCESSWIRE) +22.09%
08:00AM	Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC) (ACCESSWIRE)
Nov-20-23 09:27AM	Why Is Tharimmune (THAR) Stock Down 8% Today? (InvestorPlace) -17.76%
Nov-17-23 07:00AM	Tharimmune Announces 1-for-25 Reverse Stock Split (ACCESSWIRE) +16.67%
Nov-07-23 08:20AM	Why Is Tharimmune (THAR) Stock Up 113% Today? (InvestorPlace) +64.87%
Nov-06-23 05:35PM	Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis (ACCESSWIRE)
Sep-22-23 08:30AM	Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. (ACCESSWIRE)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire) -5.56%
Sep-11-23 11:51AM	Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis (GlobeNewswire) -8.12%
Sep-08-23 02:30PM	Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 (GlobeNewswire)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-09-23 08:47AM	Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023 (GlobeNewswire)
Jul-20-23 08:00AM	Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215 (GlobeNewswire) +8.08%
Jul-10-23 08:47AM	Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics (GlobeNewswire)
Jul-06-23 08:30AM	Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers (GlobeNewswire)
May-15-23 08:47AM	Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson (GlobeNewswire) +5.49%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-02-23 04:05PM	Hillstream BioPharma Announces Closing of Public Offering of Common Stock (GlobeNewswire) -7.08%
08:47AM	Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences (GlobeNewswire)
Apr-27-23 09:50PM	Hillstream BioPharma Announces Pricing of Public Offering (GlobeNewswire) +53.56% -59.49%

Canton Strategic Holdings, Inc. is the first publicly traded company to leverage Canton Coin and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets. It drives value through activities on the Canton Network. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

CEO & Chairman of the BoardMr. Mark Wendland

PresidentMr. Mark Toomey

Chief Financial OfficerMr. Jacob Asbury

Chief Operating OfficerMs. Angela Dominy Radkowski

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stetz Gary S.	Director	May 22 '26	Sale	3.42	87,851	300,507	146,675	May 27 06:35 PM
Stetz Gary S.	Director	May 26 '26	Sale	3.47	12,500	43,375	134,175	May 27 06:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CNTN

Canton Strategic Holdings Inc

Upgrade your Finviz experience